Your browser doesn't support javascript.
loading
Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.
Wu, Yan-Fei; Wei, Ming-Wei; Wang, Rui-Jie; Guo, Xi-Ling; Pan, Hong-Xing; Gao, Ya-Chun; Li, Xiao-Long; Wang, Xue; Ma, Xiao-Min; Wan, Peng; Zhou, Li; Zhu, Ya-Wen; Li, Jing-Xin; Zhu, Feng-Cai.
Affiliation
  • Wu YF; School of Public Health, Southeast University, Nanjing, Jiangsu Province, China.
  • Wei MW; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu Province, China.
  • Wang RJ; Clinical operation center, CanSino Biologics Inc, Tianjin, P. R. China.
  • Guo XL; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu Province, China.
  • Pan HX; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu Province, China.
  • Gao YC; Funing Country Center for Disease Control and Prevention, Yancheng, Jiangsu Province, China.
  • Li XL; Clinical operation center, CanSino Biologics Inc, Tianjin, P. R. China.
  • Wang X; Clinical operation center, CanSino Biologics Inc, Tianjin, P. R. China.
  • Ma XM; Clinical operation center, CanSino Biologics Inc, Tianjin, P. R. China.
  • Wan P; Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Zhou L; Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu Province, China.
  • Zhu YW; Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Li JX; School of Public Health, Southeast University, Nanjing, Jiangsu Province, China.
  • Zhu FC; NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, Jiangsu Province, China.
Expert Rev Vaccines ; 22(1): 662-670, 2023.
Article in En | MEDLINE | ID: mdl-37432025
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 Vaccines / COVID-19 Type of study: Clinical_trials Limits: Adolescent / Adult / Humans / Middle aged Language: En Journal: Expert Rev Vaccines Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: Immunogenicity, Vaccine / COVID-19 Vaccines / COVID-19 Type of study: Clinical_trials Limits: Adolescent / Adult / Humans / Middle aged Language: En Journal: Expert Rev Vaccines Year: 2023 Document type: Article